CN107233611A - 一种多功能纳米纤维创面修复生物敷料及其制备方法 - Google Patents
一种多功能纳米纤维创面修复生物敷料及其制备方法 Download PDFInfo
- Publication number
- CN107233611A CN107233611A CN201710436925.4A CN201710436925A CN107233611A CN 107233611 A CN107233611 A CN 107233611A CN 201710436925 A CN201710436925 A CN 201710436925A CN 107233611 A CN107233611 A CN 107233611A
- Authority
- CN
- China
- Prior art keywords
- spinning solution
- wound repair
- syringe needle
- spinning
- biological dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002121 nanofiber Substances 0.000 title claims abstract description 43
- 230000037314 wound repair Effects 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000009987 spinning Methods 0.000 claims abstract description 108
- 239000000463 material Substances 0.000 claims abstract description 45
- 238000010041 electrostatic spinning Methods 0.000 claims abstract description 18
- 239000002131 composite material Substances 0.000 claims abstract description 16
- 208000012886 Vertigo Diseases 0.000 claims description 107
- 239000000835 fiber Substances 0.000 claims description 35
- 229920002521 macromolecule Polymers 0.000 claims description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 27
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 26
- 230000015572 biosynthetic process Effects 0.000 claims description 25
- 238000003786 synthesis reaction Methods 0.000 claims description 24
- 229920001610 polycaprolactone Polymers 0.000 claims description 21
- 239000004632 polycaprolactone Substances 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 20
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 19
- 239000004626 polylactic acid Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000004814 polyurethane Substances 0.000 claims description 17
- 239000008204 material by function Substances 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 239000003242 anti bacterial agent Substances 0.000 claims description 11
- 229940088710 antibiotic agent Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 229940088598 enzyme Drugs 0.000 claims description 10
- 229940088597 hormone Drugs 0.000 claims description 10
- 239000005556 hormone Substances 0.000 claims description 10
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 9
- 229920002635 polyurethane Polymers 0.000 claims description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 8
- 239000003431 cross linking reagent Substances 0.000 claims description 8
- 229920005615 natural polymer Polymers 0.000 claims description 7
- 229920001661 Chitosan Polymers 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 239000005030 aluminium foil Substances 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 claims description 4
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 229960003276 erythromycin Drugs 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 4
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 4
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims description 3
- 108010004032 Bromelains Proteins 0.000 claims description 3
- 102000016943 Muramidase Human genes 0.000 claims description 3
- 108010014251 Muramidase Proteins 0.000 claims description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 3
- 108090000526 Papain Proteins 0.000 claims description 3
- 235000019835 bromelain Nutrition 0.000 claims description 3
- -1 clostridiopetidase A Substances 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229960000274 lysozyme Drugs 0.000 claims description 3
- 239000004325 lysozyme Substances 0.000 claims description 3
- 235000010335 lysozyme Nutrition 0.000 claims description 3
- 229960003128 mupirocin Drugs 0.000 claims description 3
- 229930187697 mupirocin Natural products 0.000 claims description 3
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims description 3
- 229960001699 ofloxacin Drugs 0.000 claims description 3
- 229940055729 papain Drugs 0.000 claims description 3
- 235000019834 papain Nutrition 0.000 claims description 3
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 230000029663 wound healing Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 8
- 231100000241 scar Toxicity 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 5
- 206010030113 Oedema Diseases 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 208000032544 Cicatrix Diseases 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000037387 scars Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 92
- 206010052428 Wound Diseases 0.000 description 32
- 208000027418 Wounds and injury Diseases 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000001523 electrospinning Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0061—Electro-spinning characterised by the electro-spinning apparatus
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0061—Electro-spinning characterised by the electro-spinning apparatus
- D01D5/0069—Electro-spinning characterised by the electro-spinning apparatus characterised by the spinning section, e.g. capillary tube, protrusion or pin
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0061—Electro-spinning characterised by the electro-spinning apparatus
- D01D5/0092—Electro-spinning characterised by the electro-spinning apparatus characterised by the electrical field, e.g. combined with a magnetic fields, using biased or alternating fields
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F8/00—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof
- D01F8/02—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from cellulose, cellulose derivatives, or proteins
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F8/00—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof
- D01F8/04—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers
- D01F8/10—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers with at least one other macromolecular compound obtained by reactions only involving carbon-to-carbon unsaturated bonds as constituent
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F8/00—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof
- D01F8/04—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers
- D01F8/14—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers with at least one polyester as constituent
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F8/00—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof
- D01F8/04—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers
- D01F8/16—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers with at least one other macromolecular compound obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds as constituent
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F8/00—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof
- D01F8/18—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from other substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/43—Hormones, e.g. dexamethasone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Textile Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mechanical Engineering (AREA)
- Dispersion Chemistry (AREA)
- Toxicology (AREA)
- Manufacturing & Machinery (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种多功能纳米纤维创面修复生物敷料及其制备方法,属于纳米纤维材料技术领域。是由三针头静电纺丝装置制备的,其中针头A、针头B和针头C中分别装有负载不同功能性物质的高分子纺丝溶液,三针头同时纺丝获得多功能复合纳米纤维敷料。本发明可以满足人们对创面修复生物敷料的日益需求,其多功能性可以有效的提供抑制瘢痕、消除水肿、抗菌防感染等多方面作用,有效加速创面愈合。此外该发明制备过程简单易行,易实现工业化生产。
Description
技术领域
本发明属于纳米纤维材料技术领域,具体涉及一种纳米纤维创面修复生物敷料及其制备方法。
背景技术
我国每年有数百万人因意外事故和手术造成皮肤损伤,伤后瘢痕是影响患者预后生活质量的重要因素,传统材料已经不能满足精细调控创面愈合的需求,因此皮肤修复材料仿生化、功能化成为国内外学者研究的热点。静电纺丝方法制备的纳米纤维其特殊的3D结构非常类似人体的细胞外基质结构,有利于细胞的粘附和繁殖,通过此方法制备的纳米纤维在生物医学领域具有良好的应用价值。近些年静电纺纳米纤维用于创面修复生物敷料的研究得到了研究者们广泛的关注,多种合成高分子以及天然高分子已经被纺制成纳米纤维并用于创面敷料领域。曹谊团队以PGA复合患者自体细胞,研制了一种组织工程化皮肤。马建标等人制备以壳聚糖为主要材料促进人成纤维细胞生长的海绵状修复材料。理想的创面修复生物敷料应该具有良好的生物相容性、较好的吸水性、透气性、黏附性和抗菌、止血作用等。为了提高纺丝纤维敷料的功能性,一些功能性物质如抗生素、生长因子等被掺杂到纺丝纤维中来提高其对创面的愈合效果。有研究报道了PLGA/胶原为高分子载体负载表皮细胞生长因子促进创面修复。以及在材料中负载多种抗生素类药物制备抗菌性能材料。单一组分的纺丝溶液负载单一的功能性物质制备的纤维敷料其功能性单一,不能同时满足多功能性创面修复生物敷料的要求。考虑到不同功能性物质溶解性的差异,多种功能性物质无法同时溶解到一种纺丝溶液中,并且一些可同时溶解的功能性物质在同一溶液中也会相互干扰,不能达到一加一大于二的效果。研究者们为了解决这个问题,提出了通过制备多层复合纤维敷料每层纤维中负载不同功能性物质,或者通过同轴静电纺丝设备每轴壳层中添加不同高分子不同功能性物质等方法制备多功能性创面修复生物敷料。P.Selcan制备PCL/PLLA和PCL/胶原双层纤维负载成纤维细胞生长因子促进创面愈合。但是多层复合方法中与创面直接接触的层中功能性物质可以有效与创面作用,而不能与创面直接接触层中的功能性物质与创面作用受到阻碍。同轴纺丝方法中其纺丝设备复杂可控性难也限制其工业化应用。
发明内容
本发明提供一种多功能纳米纤维创面修复生物敷料及其制备方法,基于以上原因,本发明通过多针头纺丝工艺,每个针头中含有的高分子溶液纺丝液中都负载一种具有不同作用的功能性物质,多针头同时纺丝得到单层的多种高分子负载不同功能性物质的复合纤维膜。由于不同种功能性物质分别负载到不同的高分子中,其相互之间并不会相互干扰;通过多针头的引入不用考虑不同油溶水溶功能性物质之间的溶解差异而无法同时纺丝的困扰;此外由于纤维的同时沉积得到的复合纤维膜多种功能性物质可以同时作用在创面患处起到多功能性的作用,从而获得一种多功能纳米纤维创面修复生物敷料。
本发明采取的技术方案是:
该多功能纳米纤维创面修复生物敷料是由三针头静电纺丝装置制备的,其中针头A、针头B和针头C中分别装有负载不同功能性物质的高分子纺丝溶液,三针头同时纺丝获得多功能复合纳米纤维敷料。
三针头纺丝的引入可以有效的解决不同溶解性的功能物质不能同时溶解到一种纺丝溶液中的难题;不同功能性物质可以分散在不同纤维中可以消除功能性物质之间的相互干扰;三针头同时纺丝得到的纤维含有负载三种功能性物质的纤维可以与创面直接有效接触。
所述的针头A中纺丝溶液负载抗生素类药物,其作用为提高敷料的抗菌活性,有效减轻炎症反应、防治感染,为创面提供一个无菌环境有利于创面愈合;负载抗生素类药物的纤维高分子载体为生物相容的合成高分子聚乳酸PLA、聚己内酯PCL、聚氨酯PU、聚乳酸-乙醇酸共聚物PLGA;所述的抗生素类药物为莫匹罗星、红霉素、左氧氟沙星中的一种;纺丝液溶剂为N,N-二甲基甲酰胺、丙酮、氯仿、乙醇中的一种或者两种混合;
所述的针头B中纺丝溶液负载酶类物质,其作用为溶解创面处坏死组织,促进渗出液再吸收,消除水肿促进创面快速愈合;负载酶类物质的纤维高分子载体为水溶性合成高分子聚乙烯醇PVA及生物天然高分子羧甲基壳聚糖、丝胶、海藻酸钠中的一种或两种;所述的酶类物质为菠萝蛋白酶、溶菌酶、木瓜蛋白酶、胶原酶;纺丝液溶剂为水;
所述的针头C中纺丝溶液负载激素类药物,其作用为能促进上皮细胞生长,减少胶原合成,抑制创面处瘢痕的形成;负载激素类药物的纤维高分子载体为生物相容的合成高分子聚乳酸PLA、聚己内酯PCL、聚氨酯PU、聚乳酸-乙醇酸共聚物PLGA;所述的激素类药物为曲安奈德、得保松;纺丝液溶剂为N,N-二甲基甲酰胺、丙酮、氯仿、乙醇中的一种或者两种。
一种多功能纳米纤维创面修复生物敷料的制备方法,包括以下步骤:
(1)配置三种负载不同功能性物质的纺丝溶液A、纺丝溶液B和纺丝溶液C,其中:
配置纺丝溶液A:将生物相容的合成高分子溶解在溶剂a中,其中高分子质量浓度为5wt%~35wt%,后加入相对于高分子质量的0.5wt%~5wt%的抗生素类药物,搅拌至溶液透明均一,即得到纺丝溶液A;
配置纺丝溶液B:将水溶性合成高分子或天然高分子溶解在水中,其中高分子质量浓度为6wt%~20wt%,后加入相对于高分子质量的0.1wt%~2wt%的交联剂,后再加入相对于高分子质量的1wt%~20wt%的酶类物质,搅拌至溶液透明均一,即得到纺丝溶液B;
配置纺丝溶液C:将生物相容的合成高分子溶解在溶剂a中,其中高分子质量浓度为配置5wt%~35wt%,后加入相对于高分子质量的0.5wt%~30wt%的激素类药物,搅拌至溶液透明均一即得到纺丝溶液C;
(2)将上述纺丝溶液A、纺丝溶液B、纺丝溶液C分别装载到三针头静电纺丝装置的针头A、针头B、针头C中进行多针头静电纺丝,纤维直径分布为200~1500nm;得到功能纳米纤维创面修复生物敷料。
所述步骤(1)中的溶剂a为N,N-二甲基甲酰胺、丙酮、氯仿、乙醇中的一种或者两种。
所述步骤(1)配置纺丝溶液A中的生物相容的合成高分子为聚乳酸PLA、聚己内酯PCL、聚氨酯PU或聚乳酸-乙醇酸共聚物PLGA。
所述步骤(1)配置纺丝溶液C中的生物相容的合成高分子为聚乳酸PLA、聚己内酯PCL、聚氨酯PU或聚乳酸-乙醇酸共聚物PLGA。
所述步骤(1)配置纺丝溶液B中的水溶性合成高分子为聚乙烯醇PVA,天然高分子为羧甲基壳聚糖、丝胶、海藻酸钠中的一种或两种复合。
所述步骤(1)配置纺丝溶液B中的交联剂为50%戊二醛或京尼平。
所述步骤(2)中的静电纺丝具体为:三针头成等边三角形分布,针头之间的距离为5~20厘米,静电纺丝装置的工作电压为15~30千伏,以铝箔为阴极接收产物,接收距离为10~30厘米。
本发明的有益效果:该敷料产品原料高分子为生物高分子,无毒,体内生物相容性,降解性良好。静电纺丝技术制备的纳米纤维敷料具有多孔结构、高的孔隙率,高的水汽和氧气透过;其模拟细胞外基质的微观结构能够促进细胞的迁移和繁殖。三针头静电纺丝装置制备复合纤维敷料,每个针头中装有负载不同功能性物质的纺丝溶液,三针头同时纺丝即获得多功能复合纳米纤维敷料。三针头纺丝的引入可以有效的解决不同溶解性的功能物质不能同时溶解到一种纺丝溶液中的难题;不同功能性物质可以分散在不同纤维中可以消除功能性物质之间的相互干扰;三针头同时纺丝得到的纤维含有负载三种功能性物质的纤维可以与创面直接同时有效接触。多功能纳米纤维创面修复生物敷料的制备可以满足人们对创面修复生物敷料的日益需求,其多功能性可以有效的提供抑制瘢痕、消除水肿、抗菌防感染等多方面作用,有效加速创面愈合。此外该发明制备过程简单易行,易实现工业化生产。
附图说明
图1是三针头纺丝制备本发明的示意图;
图2是实施例1分别用不同材料处理下的金黄色葡萄球菌的细菌活性图;
图3是实施例1分别用不同材料处理下成纤维细胞Ⅰ型胶原表达情况图;
图4是实施例1分别用单纯高分子纳米纤维对照和本发明制备的多功能纳米纤维创面修复生物敷料处理创面愈合情况对比图;
图5是实施例3中得到的多功能纳米纤维创面修复生物敷料的扫面电镜照片。
具体实施方式
下面通过实施例对本发明做进一步的描述,但本发明的实施方式不限于此,不能理解为对发明保护范围的限制。
实施例1
(1)配置三种负载不同功能性物质的纺丝溶液A、纺丝溶液B和纺丝溶液C,其中:
纺丝溶液A配置:将聚乳酸溶解在溶剂氯仿中,其中高分子质量浓度为5wt%,后加入相对于高分子质量的0.5wt%的抗生素类药物莫匹罗星,搅拌至溶液透明均一即得到纺丝溶液A;
纺丝溶液B配置:将水溶性合成高分子聚乙烯醇溶解在水中,其中高分子质量浓度为6wt%,后加入相对于高分子质量的2wt%的交联剂戊二醛,后再加入相对于高分子质量的1wt%的酶类物质菠萝蛋白酶,搅拌至溶液透明均一即得到纺丝溶液B;
纺丝溶液C配置:将聚氨酯溶解在溶剂N,N-二甲基甲酰胺中,其中高分子质量浓度为35wt%,后加入相对于高分子质量的30wt%的激素类药物得保松,搅拌至溶液透明均一即得到纺丝溶液C;
(2)将纺丝溶液A、纺丝溶液B、纺丝溶液C,分别装载到针头A、B、C中进行多针头静电纺丝(如图1),三针头成等边三角形分布,针头之间的距离为20厘米,电纺丝设备的工作电压为15千伏,以铝箔为阴极接收产物,接收距离为10厘米。得到的复合多功能纳米纤维创面修复生物敷料纤维直径分布为200~1000nm。
抗菌实验测试:抗菌测试根据AATCC 100-1999测试标准进行测试,选用在烧伤伤口初期常见的金色葡萄球菌做为测试菌种。抗菌能力通过评估细菌培养液在620nm处的光学强度来评价细菌数量,强度越大细菌数越多。将制备的多功能纳米纤维伤口敷料与金色葡萄球菌培养液一同培养,检测不同时间下菌液的光学强度。对照组使用纺丝溶液A、B、C中不加任何功能性物质,三针头同时纺丝得到的复合纤维膜与菌液一同培养,空白组不加任何纤维。结果显示,空白组与对照组的细菌缓慢生长,而实验组也就是与制备的多功能纳米纤维伤口敷料共培养的细菌几乎没有增长。通过与空白组细菌数的比值也就是光学强度的比值,在24小时的杀菌率可以达到97.2%(如图2)。
瘢痕评价实验:通过与材料共培养的细胞的胶原表达情况来说明材料抑制瘢痕的效果。材料灭菌后铺于24孔板中,接种人瘢痕组织培养细胞(4代)104/孔,5%CO2,37℃孵箱培养48小时,通过western blot检测细胞Ⅰ型胶原表达情况。空白组为没有材料共培养,对照组为纺丝溶液A、B、C中不加任何功能性物质,三针头同时纺丝得到的复合纤维膜共培养,实验组为制备的多功能纳米纤维伤口敷料共培养。如图3显示:与对照组和PCL相比,实验组本发明制备的多功能纳米纤维伤口敷料材料Ⅰ型胶原表达显著下降,证实其有抑制瘢痕形成的性质。
小鼠体内创面愈合实验:选取健康成年雌性大鼠,在其背部剃毛,制造直径1cm的圆形创面两个。其中一个创面用步骤(4)得到的复合多功能纳米纤维创面修复生物敷料处理覆盖,另一个创面用纺丝溶液制备单纯纳米纤维敷料处理作为对照组。通过观察不同天数时两个创面的愈合情况来说明敷料功效。实验结果显示本发明制备的多功能纳米纤维创面修复生物敷料处理的创面10天后完全愈合,而对照纤维处理的创面10天后创面愈合了78.8%(如图4)。
实施例2
(1)配置三种负载不同功能性物质的纺丝溶液A、纺丝溶液B和纺丝溶液C,其中:
纺丝溶液A配置:将聚己内酯溶解在溶剂氯仿和N,N-二甲基甲酰胺的混合溶液中,其中高分子质量浓度为12wt%,后加入相对于高分子质量的5wt%的抗生素类药物红霉素,搅拌至溶液透明均一即得到纺丝溶液A;
纺丝溶液B配置:将水溶性合成高分子聚乙烯醇和羧甲基壳聚糖溶解在水中,其中高分子质量浓度为20wt%,后加入相对于高分子质量的0.1wt%的交联剂京尼平,后再加入相对于高分子质量的20wt%的酶类物质木瓜蛋白酶,搅拌至溶液透明均一即得到纺丝溶液B;
纺丝溶液C配置:将聚乳酸溶解在溶剂氯仿和N,N-二甲基甲酰胺中,其中高分子质量浓度为18wt%,后加入相对于高分子质量的0.5wt%的激素类药物曲安奈德,搅拌至溶液透明均一即得到纺丝溶液C;
(2)将纺丝溶液A、B、C,分别装载到针头A、B、C中进行多针头静电纺丝,三针头成等边三角形分布,针头之间的距离为5厘米,电纺丝设备的工作电压为30千伏,以铝箔为阴极接收产物,接收距离为30厘米。得到的复合多功能纳米纤维创面修复生物敷料纤维直径分布为700~1200nm;
小鼠体内创面愈合实验按照实施例1中进行,实验结果显示本发明制备的多功能纳米纤维创面修复生物敷料处理的创面9天后完全愈合,而对照组的创面9天后创面愈合了70.6%。
实施例3
(1)配置三种负载不同功能性物质的纺丝溶液A、纺丝溶液B和纺丝溶液C,其中:
纺丝溶液A配置:将聚乳酸-乙醇酸共聚物在溶剂氯仿和丙酮的混合溶液中,其中高分子质量浓度为35wt%,后加入相对于高分子质量的3wt%的抗生素类药物左氧氟沙星,搅拌至溶液透明均一即得到纺丝溶液A;
纺丝溶液B配置:将水溶性合成高分子聚乙烯醇和海藻酸钠溶解在水中,其中高分子质量浓度为12wt%,后加入相对于高分子质量的1wt%的交联剂京尼平,后再加入相对于高分子质量的3wt%的酶类物质溶菌酶,搅拌至溶液透明均一即得到纺丝溶液B;
纺丝溶液C配置:将聚己内酯溶解在溶剂氯仿和N,N-二甲基甲酰胺中,其中高分子质量浓度为20wt%,后加入相对于高分子质量的15wt%的激素类药物得保送,搅拌至溶液透明均一即得到纺丝溶液C;
(2)将纺丝溶液A、B、C,分别装载到针头A、B、C中进行多针头静电纺丝,三针头成等边三角形分布,针头之间的距离为10厘米,电纺丝设备的工作电压为20千伏,以铝箔为阴极接收产物,接收距离为25厘米。得到的复合多功能纳米纤维创面修复生物敷料纤维直径分布为600~1500nm(如图5);
小鼠体内创面愈合实验按照实施例1中进行,实验结果显示本发明制备的多功能纳米纤维创面修复生物敷料处理的创面11天后完全愈合,而用对照组处理的创面11天后创面愈合了83.9%。
实施例4
(1)配置三种负载不同功能性物质的纺丝溶液A、纺丝溶液B和纺丝溶液C,其中:
纺丝溶液A配置:将聚乳酸-乙醇酸共聚物在溶剂氯仿中,其中高分子质量浓度为20wt%,后加入相对于高分子质量的5wt%的抗生素类药物红霉素,搅拌至溶液透明均一即得到纺丝溶液A;
纺丝溶液B配置:将水溶性合成高分子聚乙烯醇溶解在水中,其中高分子质量浓度为15wt%,后加入相对于高分子质量的2wt%的交联剂戊二醛,后再加入相对于高分子质量的11wt%的酶类物质胶原酶,搅拌至溶液透明均一即得到纺丝溶液B;
纺丝溶液C配置:将聚乳酸溶解在溶剂氯仿和N,N-二甲基甲酰胺混合溶液中,其中高分子质量浓度为5wt%,后加入相对于高分子质量的20wt%的激素类药物曲安奈德,搅拌至溶液透明均一即得到纺丝溶液C;
(2)将纺丝溶液A、B、C,分别装载到针头A、B、C中进行多针头静电纺丝,三针头成等边三角形分布,针头之间的距离为15厘米,电纺丝设备的工作电压为30千伏,以铝箔为阴极接收产物,接收距离为10厘米。得到的复合多功能纳米纤维创面修复生物敷料纤维直径分布为500~1400nm;
小鼠体内创面愈合实验按照实施例1中进行,实验结果显示本发明制备的多功能纳米纤维创面修复生物敷料处理的创面10天后完全愈合,而用对照组处理的创面10天后创面愈合了78.4%。
Claims (10)
1.一种多功能纳米纤维创面修复生物敷料,其特征在于:是由三针头静电纺丝装置制备的,其中针头A、针头B和针头C中分别装有负载不同功能性物质的高分子纺丝溶液,三针头同时纺丝获得多功能复合纳米纤维敷料。
2.根据权利要求1所述的一种多功能纳米纤维创面修复生物敷料,其特征在于:所述的针头A中负载的功能性物质为抗生素类药物为莫匹罗星、红霉素或左氧氟沙星其中一种,纤维载体高分子为生物相容的合成高分子聚乳酸PLA、聚己内酯PCL、聚氨酯PU、聚乳酸-乙醇酸共聚物PLGA,纺丝液溶剂为N,N-二甲基甲酰胺、丙酮、氯仿、乙醇中的一种或者两种。
3.根据权利要求1所述的一种多功能纳米纤维创面修复生物敷料,其特征在于:所述的针头B中负载的功能性物质为酶类物质为菠萝蛋白酶、溶菌酶、木瓜蛋白酶、胶原酶,纤维载体高分子为水溶性合成高分子聚乙烯醇PVA及生物天然高分子羧甲基壳聚糖、丝胶、海藻酸钠中的一种或两种,纺丝液溶剂为水。
4.根据权利要求1所述的一种多功能纳米纤维创面修复生物敷料,其特征在于:所述的针头C中负载的功能性物质为激素类药物为曲安奈德、得保松,纤维载体高分子为生物相容的合成高分子聚乳酸PLA、聚己内酯PCL、聚氨酯PU、聚乳酸-乙醇酸共聚物PLGA,纺丝液溶剂为N,N-二甲基甲酰胺、丙酮、氯仿、乙醇中的一种或者两种。
5.如权利要求1所述的一种多功能纳米纤维创面修复生物敷料的制备方法,包括以下步骤:
(1)配置三种负载不同功能性物质的纺丝溶液A、纺丝溶液B和纺丝溶液C,其中:
配置纺丝溶液A:将生物相容的合成高分子溶解在溶剂a中,其中高分子质量浓度为5wt%~35wt%,后加入相对于高分子质量的0.5wt%~5wt%的抗生素类药物,搅拌至溶液透明均一,即得到纺丝溶液A;
配置纺丝溶液B:将水溶性合成高分子或天然高分子溶解在水中,其中高分子质量浓度为6wt%~20wt%,后加入相对于高分子质量的0.1wt%~2wt%的交联剂,后再加入相对于高分子质量的1wt%~20wt%的酶类物质,搅拌至溶液透明均一,即得到纺丝溶液B;
配置纺丝溶液C:将生物相容的合成高分子溶解在溶剂a中,其中高分子质量浓度为配置5wt%~35wt%,后加入相对于高分子质量的0.5wt%~30wt%的激素类药物,搅拌至溶液透明均一即得到纺丝溶液C;
(2)将上述纺丝溶液A、纺丝溶液B、纺丝溶液C分别装载到三针头静电纺丝装置的针头A、针头B、针头C中进行多针头静电纺丝,纤维直径分布为200~1500nm;得到功能纳米纤维创面修复生物敷料。
6.根据权利要求5所述的一种多功能纳米纤维创面修复生物敷料的制备方法,其特征在于:所述步骤(1)中的溶剂a为N,N-二甲基甲酰胺、丙酮、氯仿、乙醇中的一种或者两种。
7.根据权利要求5所述的一种多功能纳米纤维创面修复生物敷料的制备方法,其特征在于:所述步骤(1)中配置纺丝溶液A中的生物相容的合成高分子为聚乳酸PLA、聚己内酯PCL、聚氨酯PU或聚乳酸-乙醇酸共聚物PLGA。
8.根据权利要求5所述的一种多功能纳米纤维创面修复生物敷料的制备方法,其特征在于:所述步骤(1)中配置纺丝溶液B中的水溶性合成高分子为聚乙烯醇PVA,天然高分子为羧甲基壳聚糖、丝胶、海藻酸钠中的一种或两种,交联剂为50%戊二醛或京尼平。
9.根据权利要求5所述的一种多功能纳米纤维创面修复生物敷料的制备方法,其特征在于:所述步骤(1)中配置纺丝溶液C中的生物相容的合成高分子为聚乳酸PLA、聚己内酯PCL、聚氨酯PU或聚乳酸-乙醇酸共聚物PLGA。
10.根据权利要求5所述的一种多功能纳米纤维创面修复生物敷料的制备方法,其特征在于:所述步骤(2)中的静电纺丝具体为:三针头成等边三角形分布,针头之间的距离为5~20厘米,静电纺丝装置的工作电压为15~30千伏,以铝箔为阴极接收产物,接收距离为10~30厘米。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710436925.4A CN107233611B (zh) | 2017-06-11 | 2017-06-11 | 一种多功能纳米纤维创面修复生物敷料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710436925.4A CN107233611B (zh) | 2017-06-11 | 2017-06-11 | 一种多功能纳米纤维创面修复生物敷料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107233611A true CN107233611A (zh) | 2017-10-10 |
CN107233611B CN107233611B (zh) | 2020-07-31 |
Family
ID=59987049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710436925.4A Active CN107233611B (zh) | 2017-06-11 | 2017-06-11 | 一种多功能纳米纤维创面修复生物敷料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107233611B (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108421082A (zh) * | 2018-04-23 | 2018-08-21 | 闫金银 | 具有抑菌抗瘢痕双重作用的氧化石墨烯伤口敷料的制备方法 |
CN108939136A (zh) * | 2018-08-20 | 2018-12-07 | 重庆医科大学附属永川医院 | 一种用于鼻部填充止血的敷料及其制备方法 |
CN109260507A (zh) * | 2018-10-31 | 2019-01-25 | 广东泰宝医疗科技股份有限公司 | 一种高吸液性丝素蛋白止血膜及其制备方法 |
CN109745576A (zh) * | 2019-01-18 | 2019-05-14 | 淮南联合大学 | 一种缓释镇痛抗菌可吸收敷料及其制备方法 |
CN111793900A (zh) * | 2020-06-15 | 2020-10-20 | 中国人民解放军陆军特色医学中心 | 一种壳聚糖/聚己内酯复合纳米纤维膜材料及其应用 |
CN112195564A (zh) * | 2020-09-24 | 2021-01-08 | 浙江纳博生物质材料有限公司 | 一种具有高抗菌消臭效果的复合功能纤维材料制备方法 |
CN112709002A (zh) * | 2020-12-04 | 2021-04-27 | 广州贝奥吉因生物科技股份有限公司 | 一种海藻酸盐抗菌复合膜及其制备方法 |
CN112941726A (zh) * | 2021-01-29 | 2021-06-11 | 湖南大学 | 一种高韧性的抗菌口罩过滤层及其制备方法 |
CN113797178A (zh) * | 2021-03-29 | 2021-12-17 | 中山大学附属第三医院(中山大学肝脏病医院) | 一种多功能复合材料及其制备方法和应用 |
CN114306172A (zh) * | 2022-02-10 | 2022-04-12 | 广东英腾生物科技有限公司 | 一种美白润肤手膜及其制备方法 |
CN114344546A (zh) * | 2022-02-08 | 2022-04-15 | 南通大学 | 一种减轻疤痕产生的伤口敷料的制备方法 |
CN114732936A (zh) * | 2021-01-08 | 2022-07-12 | 陈娜 | 一种高透气性可降解的载药皮肤创伤敷料 |
CN114848887A (zh) * | 2022-05-20 | 2022-08-05 | 诺一迈尔(苏州)生命科技有限公司 | 一种纳米纤维敷料及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2467359A1 (en) * | 2000-11-17 | 2002-05-23 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen |
CN1456716A (zh) * | 2003-06-10 | 2003-11-19 | 清华大学 | 利用电纺丝制备组织工程支架材料的方法及装置 |
EP1490538B1 (en) * | 2002-04-04 | 2011-11-16 | The University of Akron, Akron Ohio | Non-woven fiber assemblies |
CN103990175A (zh) * | 2014-06-10 | 2014-08-20 | 吉林大学 | 一种药物释放可控的双层纳米纤维伤口敷料及其制备方法 |
CN105396181A (zh) * | 2015-08-24 | 2016-03-16 | 武汉医佳宝生物材料有限公司 | 一种可降解支架医用膜的制备方法 |
-
2017
- 2017-06-11 CN CN201710436925.4A patent/CN107233611B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2467359A1 (en) * | 2000-11-17 | 2002-05-23 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen |
EP1490538B1 (en) * | 2002-04-04 | 2011-11-16 | The University of Akron, Akron Ohio | Non-woven fiber assemblies |
CN1456716A (zh) * | 2003-06-10 | 2003-11-19 | 清华大学 | 利用电纺丝制备组织工程支架材料的方法及装置 |
CN103990175A (zh) * | 2014-06-10 | 2014-08-20 | 吉林大学 | 一种药物释放可控的双层纳米纤维伤口敷料及其制备方法 |
CN105396181A (zh) * | 2015-08-24 | 2016-03-16 | 武汉医佳宝生物材料有限公司 | 一种可降解支架医用膜的制备方法 |
Non-Patent Citations (2)
Title |
---|
ANTONIYA TONCHEVA 等: "Dual vs. single spinneret electrospinning for the preparation of dual drug", 《COLLOIDS AND SURFACES A: PHYSICOCHEMICAL AND》 * |
刘学凯 等: "电场均匀性对三孔和三针头静电纺丝的影响", 《东华大学学报(自然科学版)》 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108421082A (zh) * | 2018-04-23 | 2018-08-21 | 闫金银 | 具有抑菌抗瘢痕双重作用的氧化石墨烯伤口敷料的制备方法 |
CN108939136A (zh) * | 2018-08-20 | 2018-12-07 | 重庆医科大学附属永川医院 | 一种用于鼻部填充止血的敷料及其制备方法 |
CN108939136B (zh) * | 2018-08-20 | 2020-12-22 | 重庆医科大学附属永川医院 | 一种用于鼻部填充止血的敷料及其制备方法 |
CN109260507A (zh) * | 2018-10-31 | 2019-01-25 | 广东泰宝医疗科技股份有限公司 | 一种高吸液性丝素蛋白止血膜及其制备方法 |
CN109745576A (zh) * | 2019-01-18 | 2019-05-14 | 淮南联合大学 | 一种缓释镇痛抗菌可吸收敷料及其制备方法 |
CN111793900A (zh) * | 2020-06-15 | 2020-10-20 | 中国人民解放军陆军特色医学中心 | 一种壳聚糖/聚己内酯复合纳米纤维膜材料及其应用 |
CN112195564A (zh) * | 2020-09-24 | 2021-01-08 | 浙江纳博生物质材料有限公司 | 一种具有高抗菌消臭效果的复合功能纤维材料制备方法 |
CN112709002A (zh) * | 2020-12-04 | 2021-04-27 | 广州贝奥吉因生物科技股份有限公司 | 一种海藻酸盐抗菌复合膜及其制备方法 |
CN114732936A (zh) * | 2021-01-08 | 2022-07-12 | 陈娜 | 一种高透气性可降解的载药皮肤创伤敷料 |
CN112941726A (zh) * | 2021-01-29 | 2021-06-11 | 湖南大学 | 一种高韧性的抗菌口罩过滤层及其制备方法 |
CN113797178A (zh) * | 2021-03-29 | 2021-12-17 | 中山大学附属第三医院(中山大学肝脏病医院) | 一种多功能复合材料及其制备方法和应用 |
CN113797178B (zh) * | 2021-03-29 | 2024-03-22 | 中山大学附属第三医院(中山大学肝脏病医院) | 一种多功能复合材料及其制备方法和应用 |
CN114344546A (zh) * | 2022-02-08 | 2022-04-15 | 南通大学 | 一种减轻疤痕产生的伤口敷料的制备方法 |
CN114344546B (zh) * | 2022-02-08 | 2022-08-12 | 南通大学 | 一种减轻疤痕产生的伤口敷料的制备方法 |
CN114306172A (zh) * | 2022-02-10 | 2022-04-12 | 广东英腾生物科技有限公司 | 一种美白润肤手膜及其制备方法 |
CN114848887A (zh) * | 2022-05-20 | 2022-08-05 | 诺一迈尔(苏州)生命科技有限公司 | 一种纳米纤维敷料及其制备方法 |
CN114848887B (zh) * | 2022-05-20 | 2023-08-25 | 诺一迈尔(苏州)生命科技有限公司 | 一种纳米纤维敷料及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107233611B (zh) | 2020-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107233611A (zh) | 一种多功能纳米纤维创面修复生物敷料及其制备方法 | |
Baghersad et al. | Development of biodegradable electrospun gelatin/aloe-vera/poly (ε‑caprolactone) hybrid nanofibrous scaffold for application as skin substitutes | |
Asghari et al. | Hybrid PCL/chitosan-PEO nanofibrous scaffolds incorporated with A. euchroma extract for skin tissue engineering application | |
Fahimirad et al. | Naturally-derived electrospun wound dressings for target delivery of bio-active agents | |
Mohammadi et al. | An excellent nanofibrous matrix based on gum tragacanth-poly (Ɛ-caprolactone)-poly (vinyl alcohol) for application in diabetic wound healing | |
Joseph et al. | Recent advances in electrospun polycaprolactone based scaffolds for wound healing and skin bioengineering applications | |
Cao et al. | Double crosslinked HLC-CCS hydrogel tissue engineering scaffold for skin wound healing | |
Qiu et al. | Bacterial cellulose and bacterial cellulose-vaccarin membranes for wound healing | |
CN103990175B (zh) | 一种药物释放可控的双层纳米纤维伤口敷料及其制备方法 | |
Wei et al. | The multifunctional wound dressing with core–shell structured fibers prepared by coaxial electrospinning | |
CN102580166A (zh) | 一种医用仿生透明薄膜植入材料及其制备方法和应用 | |
US20190216984A1 (en) | Vascularized full thickness tissue-engineered skin assembled by hydrogel, nanofibrous scaffolds and skin cell layers and preparation method thereof | |
CN104013995A (zh) | 氧化壳聚糖接枝改性猪真皮胶原微纳纤维膜及其制备方法 | |
CN106390177A (zh) | 一种壳聚糖基多层纳米纤维膜敷料及其制备方法和应用 | |
Wang et al. | Preparation of Centella asiatica loaded gelatin/chitosan/nonwoven fabric composite hydrogel wound dressing with antibacterial property | |
CN110193098B (zh) | 一种多层梯度生物膜及其制备方法 | |
CN107881650A (zh) | 一种同轴双层静电纺丝制备具有芯/壳包埋结构的纳米纤维膜的方法及其应用 | |
CN109381732A (zh) | 负载生长因子小分子抑制剂的静电纺丝敷料、其制备方法及应用 | |
CN102560888A (zh) | 负载水溶性维生素e的丝素蛋白纳米纤维膜及其制备方法 | |
CN107737364A (zh) | 一种创伤敷料及其制备方法 | |
CN110292652A (zh) | 巯基苯硼酸活化金纳米颗粒、其制备方法及应用 | |
CN103751848A (zh) | 一种抗菌修复型静电纺丝胶原蛋白-细菌纤维素复合纳米纤维支架的制备方法及其应用 | |
CN111588901A (zh) | 一种促进糖尿病溃疡血管化修复的自组装纳米纤维敷料、制备方法及应用 | |
Aleemardani et al. | A hydrogel–fiber–hydrogel composite scaffold based on silk fibroin with the dual‐delivery of oxygen and quercetin | |
Chang et al. | 3D PCL/collagen nanofibrous medical dressing for one-time treatment of diabetic foot ulcers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |